Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department

Abstract

Background: Drug survival in a real-life setting is critical to long-term use of biologics for psoriasis.

Objective: We describe our 12-year experience with biologics in psoriasis patients.

Patients and Methods: All patients treated with biologics including infliximab, adalimumab (ADA), etanercept (ETA), and ustekinumab (UST) for psoriasis vulgaris between January 2005 and December 2016 were retrospectively analyzed.

Results: In total, 545 treatment series were administered to 269 patients, including 211 treatment series with ADA, 135 with ETA, 77 with infliximab, and 122 with UST. ADA and ETA were initiated most often as first-line therapy; 65.3% of treatment sequences were discontinued. UST had the highest drug survival. The major reason for treatment termination was a loss of efficacy (44.9%). Definitive discontinuation increased with the number of biologic therapy sequences.

Limitations: Subjects were not randomized to the different treatments.

Conclusions: In a long-term real-life setting, drug survival of UST is better than that of TNF-a inhibitors for both biologic-naive and biologic-experienced patients with psoriasis.

Keywords:

• Psoriasis
• biologics
• drug survival
• safety

Disclosure statement

No potential conflict of interest was reported by the authors.

Table 4. Serious adverse events.